Global use of Haemophilus influenzae type b conjugate vaccine

Linda R Ojo; Rosalyn E O'Loughlin; Adam L Cohen; Jennifer D Loo; Karen M Edmond; Sharmila S Shetty; Allyson P Bear; Lois Privor-Dumm; Ulla K Griffiths; Rana Hajjeh

doi:10.1016/j.vaccine.2010.07.074

Global use of Haemophilus influenzae type b conjugate vaccine

Vaccine. 2010 Oct 8;28(43):7117-22. doi: 10.1016/j.vaccine.2010.07.074. Epub 2010 Aug 4.

Authors

Linda R Ojo¹, Rosalyn E O'Loughlin, Adam L Cohen, Jennifer D Loo, Karen M Edmond, Sharmila S Shetty, Allyson P Bear, Lois Privor-Dumm, Ulla K Griffiths, Rana Hajjeh

Affiliation

¹ Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-23, Atlanta, GA 30333, USA.

PMID: 20691265
DOI: 10.1016/j.vaccine.2010.07.074

Abstract

Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].

MeSH terms

Bacterial Capsules / administration & dosage*
Developing Countries
Haemophilus Infections / immunology
Haemophilus Infections / prevention & control
Haemophilus Vaccines / administration & dosage*
Humans
Immunization Programs / statistics & numerical data*
Public-Private Sector Partnerships
Vaccination / statistics & numerical data*
Vaccines, Conjugate / administration & dosage
World Health Organization

Substances

Haemophilus Vaccines
Haemophilus influenzae type b polysaccharide vaccine
Vaccines, Conjugate